Q-omics provides the consensus-scored DSCAM profile across patient tissues and cancer cell-line models. DSCAM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DSCAM is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, DSCAM RNA expression shows 14,056 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where DSCAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSCAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSCAM survival associations across molecular data types. DSCAM RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSCAM RNA expression–survival associations across cancer types. High DSCAM expression shows unfavorable associations in HNSC, LUSC and MESO, but favorable associations in SCLC, LGG and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DSCAM RNA expression.
This table summarizes DSCAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DSCAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSCAM shows lower tumor expression in LIHC, READ, BRCA and UCEC and higher tumor expression in HNSC and KICH. The HNSC box plot shows higher DSCAM RNA expression in tumor versus normal tissue (log2 FC = +0.553, t-test p < 0.001).
This table shows molecular features associated with DSCAM in patient tissues and cancer cell lines. In patient samples, DSCAM shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DSCAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
